SAN

75.84

-1.43%↓

UCB

253.8

-1.25%↓

SHL.DE

38.03

-1.3%↓

ARGX

598.8

-2.67%↓

VIE

32.64

-1.72%↓

SAN

75.84

-1.43%↓

UCB

253.8

-1.25%↓

SHL.DE

38.03

-1.3%↓

ARGX

598.8

-2.67%↓

VIE

32.64

-1.72%↓

SAN

75.84

-1.43%↓

UCB

253.8

-1.25%↓

SHL.DE

38.03

-1.3%↓

ARGX

598.8

-2.67%↓

VIE

32.64

-1.72%↓

SAN

75.84

-1.43%↓

UCB

253.8

-1.25%↓

SHL.DE

38.03

-1.3%↓

ARGX

598.8

-2.67%↓

VIE

32.64

-1.72%↓

SAN

75.84

-1.43%↓

UCB

253.8

-1.25%↓

SHL.DE

38.03

-1.3%↓

ARGX

598.8

-2.67%↓

VIE

32.64

-1.72%↓

Home・Lista de Ações・Pharming Group NV

P
Pharming Group NV

Fechado

1.334 -0.3

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.322

Máximo

1.3719999999999999

Indicadores-chave
By Trading Economics
Rendimento	8.1M 13M
Vendas	4.1M 97M
EPS	0.009
Margem de lucro	13.114
Funcionários	404
EBITDA	23M

Dividendos
By Dow Jones
Próximos Ganhos	2 de abr. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-49M 948M
Abertura anterior	1.63
Fecho anterior	1.334

Pharming Group NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de fev. de 2026, 16:05 UTC

Grandes Movimentos do Mercado

Pharming Group Falls on FDA Letter Requesting Additional Data

Comparação entre Pares

Variação de preço

Pharming Group NV Previsão

Consenso de Avaliação

By TipRanks

0 ratings

Comprar

Manter

Vender

Com base em 0 analistas que deram avaliações de ações para Pharming Group NV - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.